These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8645883)

  • 1. Methylprednisolone and cortisol metabolism during the early post-renal transplant period.
    Tornatore KM; Reed KA; Venuto RC
    Clin Transplant; 1995 Dec; 9(6):427-32. PubMed ID: 8645883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure.
    Tornatore KM; Venuto RC; Logue G; Davis PJ
    J Med; 1998; 29(3-4):159-83. PubMed ID: 9865456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients.
    Tornatore KM; Reed K; Walshe JJ; Venuto RC
    Pharmacotherapy; 1994; 14(1):111-8. PubMed ID: 8159595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics.
    Slayter KL; Ludwig EA; Lew KH; Middleton E; Ferry JJ; Jusko WJ
    Clin Pharmacol Ther; 1996 Mar; 59(3):312-21. PubMed ID: 8653994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of methylprednisolone during acute renal allograft rejection.
    Tornatore KM; Walshe JJ; Reed K; Venuto RC
    Clin Transplant; 1995 Apr; 9(2):74-8. PubMed ID: 7599405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+/CD8+ lymphocyte patterns in renal transplant recipients receiving chronic methylprednisolone.
    Tornatore KM; Reed K; Venuto RC
    J Med; 1993; 24(2-3):98-112. PubMed ID: 8105017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers.
    Booker BM; Magee MH; Blum RA; Lates CD; Jusko WJ
    Clin Pharmacol Ther; 2002 Oct; 72(4):370-82. PubMed ID: 12386639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males.
    Tornatore KM; Logue G; Venuto RC; Davis PJ
    J Clin Pharmacol; 1997 Apr; 37(4):304-11. PubMed ID: 9115056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients.
    Tornatore KM; Biocevich DM; Reed K; Tousley K; Singh JP; Venuto RC
    Transplantation; 1995 Mar; 59(5):729-36. PubMed ID: 7886801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients.
    Tornatore KM; Gilliland-Johnson KK; Farooqui M; Reed KA; Venuto RC
    J Clin Pharmacol; 2004 Sep; 44(9):1003-11. PubMed ID: 15317828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure.
    Jusko WJ; Milad MA; Ludwig EA; Lew KH; Kohli RK
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S16-9. PubMed ID: 7781199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients.
    Johnson AG; Rigby RJ; Taylor PJ; Jones CE; Allen J; Franzen K; Falk MC; Nicol D
    Clin Pharmacol Ther; 1999 Nov; 66(5):492-500. PubMed ID: 10579476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
    Varis T; Backman JT; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Mar; 67(3):215-21. PubMed ID: 10741623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
    Neumann I; Fuhrmann H; Kanzler M; Fang IF; Jaeger A; Graf H; Bayer P; Kovarik J
    Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic evaluation of short-term outcome after early corticosteroid discontinuation in kidney transplantation.
    Miura M; Ogawa Y; Kubota KC; Harada H; Shimoda N; Seki T; Hirano T; Nonomura K
    Clin Transplant; 2009 Aug; 23 Suppl 20():10-6. PubMed ID: 19594589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of peripheral blood lymphocyte sensitivity to glucocorticoids for the differentiation of high-risk patients with decreased allograft function after glucocorticoid withdrawal in renal transplantation.
    Muhetaer G; Takeuchi H; Unezaki S; Kawachi S; Iwamoto H; Nakamura Y; Shimazu M; Sugiyama K; Hirano T
    Clin Ther; 2014 Aug; 36(8):1264-72. PubMed ID: 25037282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.